CRISPR editing launches a new era in biology

Inspired by nature

Biological organisms have been subject to human manipulation for thousands of years through artificial selection and breeding. With the discovery of DNA, the quest to understand the relationship between gene sequences and their function has become the focus of biology. We can now actively change the genetic code and ask questions about how that impacts the resulting phenotype.

A new era of biological engineering

Gene editing is the process of deliberately altering the DNA sequence of genes, from changing individual nucleotides to deleting or inserting large regions of the genome. The invention of CRISPR-based gene editing was a revolutionary breakthrough that improved the precision and efficiency of edits, prompting a new era of biological engineering.

CRISPR editing relies on two essential elements: the RNA-guided nuclease enzyme that cuts DNA at a precise location and a synthetic DNA sequence that provides a template for the edit. With the right design and approach, CRISPR editing can be highly efficient and accurate, allowing scientists to generate edits faster and at a reduced cost.

Genome editing has the power to transform the way we make materials, grow food, and treat disease

CRISPR-based gene editing has the potential to revolutionize biotechnology, agriculture, and medicine, allowing scientists to develop solutions for the world’s most pressing problems. Gene editing is widely used in plant engineering to improve food cultivation, to enable the sustainable production of chemicals and materials in industrial microorganisms, and to find treatments for diseases.


With great power comes great responsibility

CRISPR technology enables breakthrough innovations by accelerating biological discovery and product innovation. However, challenges still remain with respect to the accessibility, scalability, and biosecurity considerations.

Accessibility icon

The widely used CRISPR systems are subject to many licensing limitations that hinder broad adoption of CRISPR technologies. Inscripta® democratizes genome editing by making its MAD7™ nuclease free for non-commercial academic and industrial applications. Learn more about the MAD7 nuclease and Inscripta’s MAD7 licensing program.

Scalability icon

Performing multiple CRISPR edits per experiment is desirable to accelerate experiments, but very difficult to execute. This all changes with the introduction of trackable barcodes and digital workflow in Inscripta’s Onyx® Digital Genome Engineering Platform to dramatically increase the editing throughput.

Biosecurity icon

The accessibility of CRISPR gene editing requires ensuring that genome engineering is executed safely. Inscripta’s proactive biosecurity screening process aims to identify and prevent both deliberate and accidental biorisk.